The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Bringing epcoritamab into earlier lines of therapy for DLBCL
In this video, Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, briefly discusses the potential of bringing the bispecific antibody epcoritamab into earlier lines of treatment for diffuse large B-cell lymphoma (DLBCL) to improve patient outcomes. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is an important question as well because until now, so in current days, the epcoritamab is approved as a monotherapy for the third plus line treatment. The epcoritamab plus R-CHOP is tested in the first line and if this study is successful, then definitely probably will be not so much space for the patients who fail combination of the bispecific antibody plus R-CHOP in the first line...
This is an important question as well because until now, so in current days, the epcoritamab is approved as a monotherapy for the third plus line treatment. The epcoritamab plus R-CHOP is tested in the first line and if this study is successful, then definitely probably will be not so much space for the patients who fail combination of the bispecific antibody plus R-CHOP in the first line. But in the current situation we know that we need to bring the bispecific antibodies to the second line. This is our study, is the first step, but we know about the STARGLO study, which unfortunately, it was not approved in the US because of some questions regarding the Caucasian population. But definitely, we need to improve the response of those patients in the second line as well. So it means the epco, the other bispecific antibodies, are very good candidates.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
